2006
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition
Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor–independent urokinase-type plasminogen activator inhibition. Molecular Cancer Therapeutics 2006, 5: 2685-2695. PMID: 17121915, DOI: 10.1158/1535-7163.mct-06-0142.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorFemaleFibroblastsHumansInsulin-Like Growth Factor Binding Protein 3Lung NeoplasmsMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsMiceMice, NudeNeoplasm MetastasisNIH 3T3 CellsReceptor, IGF Type 1Recombinant ProteinsSignal TransductionUrokinase-Type Plasminogen ActivatorConceptsNon-small cell lung cancerInsulin-like growth factorIGF-independent mechanismsIGFBP-3Recombinant IGFBP-3Expression/activityLung cancerNSCLC cellsMajor IGF-binding proteinProtein 3H1299 cellsLung cancer cell metastasisGrowth factorInvasion of H1299Experimental animal model systemsCell lung cancerIGF-binding proteinsLung cancer metastasisA549 NSCLC cellsMatrix metalloproteinase-2Anti-invasive activityHuman lung fibroblastsCancer cell metastasisAnimal model systemsPlasminogen activator inhibition
2005
Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy
Isobe T, Herbst RS, Onn A. Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. Seminars In Oncology 2005, 32: 315-328. PMID: 15988686, DOI: 10.1053/j.seminoncol.2005.02.016.Peer-Reviewed Original ResearchMeSH KeywordsAlkyl and Aryl TransferasesAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCyclooxygenase InhibitorsDrug Delivery SystemsErbB ReceptorsFarnesyltranstransferaseHumansLung NeoplasmsMatrix Metalloproteinase InhibitorsProtein Kinase CReceptor, ErbB-2Receptors, Vascular Endothelial Growth FactorRetinoid X ReceptorsConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerLung cancerVascular endothelial growth factorEpidermal growth factor receptorBiological therapyGrowth factorLung cancer patientsCancer-related deathLung cancer progressionClinical study designNew therapeutic strategiesEndothelial growth factorGrowth factor receptorOverall prognosisPatient survivalStandard treatmentCancer patientsConventional chemotherapyFrequent causeRadiation therapyTherapeutic approachesAnticancer arsenalTherapeutic strategies
2002
Angiogenesis as a target for cancer therapy
Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematology/Oncology Clinics Of North America 2002, 16: 1125-1171. PMID: 12512387, DOI: 10.1016/s0889-8588(02)00047-3.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAngiostatinsAnimalsAntibodies, MonoclonalAnticarcinogenic AgentsCell HypoxiaChildClinical Trials as TopicCollagenCyclooxygenase InhibitorsDrug DesignEndostatinsEndothelium, VascularEphrinsGrowth SubstancesHumansImmunotherapyIntegrin alphaVbeta3LigasesMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiceNeoplasm ProteinsNeoplasmsNeovascularization, PathologicOutcome Assessment, Health CarePeptide FragmentsPlasminogenProtease InhibitorsReceptors, Eph FamilyReceptors, Growth FactorThrombospondinsTumor Suppressor ProteinsUbiquitin-Protein LigasesVon Hippel-Lindau Tumor Suppressor ProteinAngiogenesis inhibitors in clinical development for lung cancer
Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Seminars In Oncology 2002, 29: 66-77. PMID: 11894016, DOI: 10.1053/sonc.2002.31527.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicDisease ProgressionEndothelial Growth FactorsEndpoint DeterminationEnzyme InhibitorsHumansLung NeoplasmsLymphokinesMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesNeovascularization, PathologicTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsAngiogenesis inhibitorsLung cancerClinical trialsClinical developmentPhase II trialLong-term administrationPlatinum-based therapyEarly clinical trialsReceptor-targeted agentsPrimary endpointAdvanced diseaseII trialMetastatic diseaseAdjunctive therapyProcess of angiogenesisCancer patientsField of angiogenesisEfficacious dosesClinical evaluationTumor regressionNovel agentsAntiangiogenic agentsTherapeutic targetDependence of tumorsTumor angiogenesis